Osteoimplant and methods for making

Information

  • Patent Grant
  • 9486500
  • Patent Number
    9,486,500
  • Date Filed
    Thursday, January 28, 2010
    15 years ago
  • Date Issued
    Tuesday, November 8, 2016
    8 years ago
Abstract
An osteoimplant is disclosed and includes a plurality of partially demineralized fibers. Each fiber has an elongated, thin body having a length of about 1 centimeter to about 3 centimeters. Further, the plurality of fibers engages to establish a matrix of material. The disclosure is further directed to a method of making the above-mentioned osteoimplant.
Description
FIELD OF THE DISCLOSURE

The present disclosure relates generally to orthopedics and orthopedic surgeries. More specifically, the present disclosure relates to materials and methods for treating bone voids.


BACKGROUND

Grafts that aid in the healing of damaged bone are a relatively old technology that has undergone substantial growth in light of recent advances in medicine and biology. Improved understanding of osteoinductive and osteoconductive properties of certain materials has enabled the design of implants of ever-increasing efficacy. Recent examples include U.S. Pat. No. 7,045,141 to Merboth et al., entitled “Allograft Bone Composition Having a Gelatin Binder”; U.S. Pat. No. 6,808,585 to Boyce et al., entitled “Osteogenic Implant Derived From Bone”; U.S. Pat. No. 6,548,080 to Gertzman et al., entitled “Method for Partially Demineralized Cortical Bone Constructs”; and U.S. Pat. No. 6,776,800 to Boyer, II et al., entitled “Implants Formed with Demineralized Bone”. Absorbable Collagen Sponge (“ACS”), by Integra LifeSciences Corporation (Plainsboro, N.J.), and Mastergraft® Matrix, by Medtronic Sofamor Danek (Memphis, Tenn.), are specific examples of grafts currently available on the market.


Many of these implants do not provide any structural support at the implant site. Structural support ranges from the ability to resist the tendency for compression of the graft by local tissues (space maintenance) to the ability to be weight bearing. There exist numerous situations in which it is desirable to have an implant that both aids in the re-growth of the bone at the implant site while also providing structural support, which are so-called structural implants. However, not all structural implants have the properties, such as compression resistance, necessary for certain applications.


Accordingly, it is desirable to provide an osteoimplant that provides structural capabilities, yet which provides superior osteoinductive, osteoconductive and re-absorption properties.


SUMMARY

In a particular embodiment, an osteoimplant includes a plurality of partially demineralized fibers. Each fiber has an elongated, thin body having a length of about 1 centimeter to about 3 centimeters. The plurality of fibers engage to establish a matrix of material.


In an embodiment, a method of making an osteoimplant is provided. The method includes partially demineralizing a bone to form a plurality of fibers, wherein each fiber comprises an elongated, thin body having a length of about 1 centimeter to about 3 centimeters; and forming the plurality of partially demineralized fibers into a fiber matrix.







DETAILED DESCRIPTION

A matrix material is disclosed that can be used as an osteoimplant. In a particular embodiment, the matrix material includes a plurality of fibers. Typically, each fiber has an elongated, thin body. In an embodiment, the plurality of fibers engage to form the matrix material. In a particular embodiment, the plurality of fibers have a length of about 1 centimeters to about 3 centimeters, such as about 1 centimeters to about 2 centimeters. The length of the fibers enables the matrix material to form and, in an exemplary embodiment, the length of the fibers are spatially arranged in a random-orientation. In particular, the length and random-orientation of the plurality of fibers enable the formation of an osteoimplant with desirable physical and mechanical properties. For instance, the length of the fibers and random-orientation is advantageous to form a superior osteoimplant that is compression resistant, has a desirable degradation rate, and is osteoinductive. “Osteoinductive” as used here refers to fibers that promote bone growth throughout the internal structure of the implant.


In an embodiment, the source of the fibers can be allogenic, xenogenic, autogenic, recombinant, or any combination thereof. In a particular embodiment, the plurality of fibers are obtained from an allogenic source such as, for instance, an allograft bone segment. Any allograft bone segment is appropriate that may provide fibers of the length described above. In an exemplary embodiment, the allograft bone segment may be derived from long bone sites such as the humerus, radius, ulna, femur, tibia, fibula, the bones of the hands or feet including the metacarpals, metatarsals, or phalanges, or bones from the spine, pelvis or other location. In a particular embodiment, the allograft bone segment can be machined into strips. In another embodiment, the bone segment is partially demineralized and then the fibers are machined from the partially demineralized allograft bone segment. Any reasonable method is envisioned to machine the allograft bone segment. The strips may be of any length to provide fibers having a length as described above.


In an embodiment, the allograft bone strips or allograft bone segment are partially demineralized. The term “partial demineralization” means that from about 5% to about 90% of the original mineral content of the bone segment has been removed. The amount of demineralization of the bone segment typically depends upon the desired properties of the final osteoimplant. In a particular embodiment, the partial demineralization removes about 20% to about 90%, such as about 30% to about 90%, or even about 40% to about 90% of the original mineral content from the allograft strips. The partial demineralization provides a corresponding osteoinductive matrix that has greater compression resistance than a fully demineralized fiber matrix. In a particular embodiment, the osteoimplant of the present invention is free of any fully demineralized fibers or particles.


Methods that provide for the partial demineralization of bone segment are known, and broadly involve chemically processing the bone with hydrochloric acid, chelating agents, electrolysis or performing other treatments to remove all or a portion of the minerals contained within the natural bone, leaving behind fibers having the length as defined above which form into the randomly-orientated matrix. In an embodiment, the partially demineralized fibers may be entangled in the random-orientation by any reasonable means. In an example, the partially demineralized fibers may be mechanically entangled.


In an exemplary embodiment, the fibers are chemically crosslinked after partial demineralization. In a particular embodiment, the chemical crosslinking both stiffens and bonds the fibers together. Accordingly, the use of a chemical crosslinker may further increase the compression resistance of the resulting osteoimplant. Any reasonable chemical crosslinker may be used to crosslink the fibers. In a particular embodiment, the cross-linking agent can be glutaraldehyde, genipin, formaldehyde, 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide/N-hydroxysuccinimide (EDC/NHS), or any combination thereof. Further, the cross-linking agent can be another protein cross-linking agent.


In an embodiment, any number of additives may be included within the matrix. Any reasonable additive may be included that can be envisioned for an osteoimplant. For example, the additives can include radiocontrast media, drugs, cellular matters, biological factors, or any combination thereof. In a particular embodiment, the drugs can include, for example, antibiotics, analgesics, anti-inflammatory drugs, anti-TNF-alpha, steroids, or any combination thereof. Further, the cellular matters can include, for example, bone marrow derived stem cells, lipo derived stem cells, or any combination thereof. The biological factor can include, for example, bone morphogenetic protein (BMP), growth differentiation factor (GDF), cartilage-derived morphogenetic protein (CDMP), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), LIM mineralization protein, fibroblast growth factor (FGF), osteoblast growth factor, or any combination thereof. The additives can also include additives to promote matrix formation. Additives may improve protein retention, reduce protein degradation, promote protein folding, promote water binding, promote protein-to-protein interaction, promote water immobilization, or any combination thereof. Additionally, the additives can include polysaccharides such as, for example, proteoglycans, hyaluronic acid, or combination thereof, which can attract or bind water to increase hydration of the osteoimplant site. Further additives can include osteoinductive agents. In a particular embodiment, the osteoinductive agents have bone morphogenic protein (BMP) binding capability to partially demineralized fibers, minerals, collagen, and the like. In an embodiment, the additives include demineralized bone matrix (DBM particles), ceramic particles, or combinations thereof. Any reasonable means or methods can be used to include the additive within the matrix.


In an embodiment, the matrix may be “remineralized” to precipitate mineral back onto the partially demineralized fibers. Any reasonable method may be employed to remineralize the matrix. For instance, a mineral bath can be used to provide precipitation of mineral back onto the partially demineralized fibers. The mineral and concentration thereof to remineralize the matrix can be determined based on the properties desired. In an embodiment, any appropriate mineral may be envisioned that increases the matrix stiffness, increases the osteoconductivity of the partially demineralized fibers, or combination thereof. In an exemplary embodiment, the crosslinked matrix is placed into a mineral bath of calcium salts, silicate, or combination thereof.


Once the matrix of partially demineralized fibers has been provided, the matrix may be impregnated with a slurry to provide an open porous structure throughout an internal structure of the matrix. In an embodiment, the slurry may include collagen, or any other natural or synthetic polymer envisioned. For instance, the slurry may include chitosan, hyaluronic acid, alginate, gelatin, silk, elastin, polylactic and/or lactic acid, the like, and combinations thereof. In an embodiment, the collagen may be in a solution of any reasonable concentration and particle/fiber size to provide the open porous structure of collagen throughout the internal structure of the matrix. For instance, the open porous structure creates an increase of the surface area for cell attachment and new osteoid formation once the matrix is placed at the site of the osteoimplant. Any reasonable solution may be used for the slurry. In a particular embodiment, water or a saline solution, for example, may be used to form the slurry. Materials which are sticky in texture may also assist in the adherence of the collagen to the matrix.


Any reasonable method may be employed to impregnate the matrix with the slurry. This slurry may be coated over the matrix or the matrix may be submersed partially or wholly into the slurry. The matrix may optionally be vibrated, rotated, centrifuged, or combination thereof to encourage the slurry to migrate into the matrix. In an embodiment, it may be desirable to subject the matrix to at least a mild vacuum to partially or wholly evacuate the air from the matrix. In an embodiment, the slurry further includes any reasonable ceramic or bone particles that have osteoconductivity properties. Exemplary ceramic particles include calcium phosphates, tricalcium phosphate, hydroxyapatite, silicate containing ceramics, and combinations thereof.


In an embodiment, the addition of the slurry to the matrix is followed by freeze-drying of the slurry in the matrix. Typical freeze-drying is achieved through the use of standard commercial freeze-drying equipment. In a particular embodiment, the freeze-drying of the collagen slurry in the matrix facilitates the formation of a porous structure throughout the internal structure of the matrix. The pores formed through the internal structure of the matrix may be of any reasonable size to facilitate cell attachment and new osteoid formation when the matrix is placed at the site of the osteoimplant. In an embodiment, the allograft fiber matrix can have pores of about 1.0 to about 5.0 mm diameter in size. In an embodiment, the addition of the collagen slurry provides a collagen matrix with pores large enough to allow cell migration in, such as having pores greater than about 0.01 mm diameter. In a particular embodiment, the collagen slurry after freeze drying can have pores about 0.01 mm to about 3.0 mm diameter in size.


The formation of the osteoimplant further includes cutting the matrix material into the final desired shape. The desired shape is dependent upon the site of implantation. In an embodiment, the osteoimplant may be pre-shaped for a specific target region or may be provided in a standard shape that may be later tailored by the physician for the particular requirements of the implant site. Any suitable method may be used to shape the osteoimplant and may be performed before or after the matrix is formed. Typically, the osteoimplant may be cut with any reasonable medical or surgical tool such as a saw, file, blade, and the like.


Processing of the matrix may be performed under aseptic conditions such that the final osteoimplant is sterile and does not require a terminal sterilization procedure. Alternatively, the matrix may be processed under less rigorous conditions and terminal sterilization is used to achieve sterility. Various methods of terminal sterilization may be used (such as gamma or electron beam irradiation, ethylene oxide, etc.), but should be controlled to ensure the final osteoimplant maintains appropriate biological characteristics for supporting bone growth.


Generally, the matrix, including the partially demineralized fibers and optional collagen and additives form the osteoimplant. The amount of partial demineralization and any optional additives may be chosen depending upon the properties desired for the osteoimplant. In some embodiments, the matrix consists essentially of the partially demineralized fibers as described above. As used herein, the phrase “consists essentially of” used in connection with the matrix of the osteoimplant precludes the presence of materials that affect the basic and novel characteristics of the osteoimplant, although, various additives as described above, such as chemical crosslinkers, collagen, and the above discussed additives, may be used in the osteoimplant.


It is expected that the matrix may be used as an osteoimplant that will have utility in a diverse array of procedures where bone grafting is desired. Exemplary procedures include posterolateral spinal fusion, interbody spine fusion, fracture repair, bone cyst filling, periodontal, cranial, containment of autograft, maxillofacial, and other procedures where bone grafting is desirable. In an embodiment, the osteoimplant may be used for long bone segmental defects, alveolar bone ridge grafting, repairing calvarial bone defects, and the like.


Once formed into a matrix, the matrix exhibits mechanical properties that advantageously enhance the performance of the osteoimplant formed of the matrix. In particular, the osteoimplant may exhibit desirable mechanical properties, such as compression resistance. In an exemplary embodiment, the hydrated matrix exhibits a compression resistance of at least about 2 MPa, for example, measured using standard compression test methods. In particular, the compression resistance may be at least about 5 MPa, such as at least about 10 MPa, or even at least about 15 MPa. In a particular embodiment, the compression resistance provides an osteoimplant that withstands drilling during a surgical procedure. For instance, any type of screws, spikes, and the like may be used to fasten the osteoimplant within the implant site.


In addition, the osteoimplant may be evaluated for performance in producing characteristics desirable for the osteoimplant such as, for example, the matrix retaining its shape and structure for several weeks after implantation. In an exemplary embodiment, the matrix exhibits a degradation rate of at least about 20% six months after implantation. In particular, the degradation rate may be at least about 30% six months after implantation, such as at least about 40% six months after implantation, or even at least about 50% six months after implantation. The degradation rate is desirable for providing structural integrity at the implantation site while bone growth occurs throughout the internal structure of the matrix.


Further, the osteoimplant is osteoinductive and is an ideal bone grafting matrix. For instance, bone growth replaces at least about 20% of the implant after six months implantation, such as at least about 30% of the implant after six months implantation. In a particular embodiment, the osteoimplant is osteoinductive, compression resistant, and has an exemplary degradation rate. For instance, the osteoinductive osteoimplant has a compression resistance of at least about 2 MPa, a degradation rate of at least about 20% six months after implantation, and bone growth replacing at least about 20% of the implant after six months implantation. Accordingly, the osteoinductive osteoimplant is highly compression resistant, retains its shape and structure, and promotes bone growth throughout the matrix.


The above-disclosed subject matter is to be considered illustrative, and not restrictive, and the appended claims are intended to cover all such modifications, enhancements, and other embodiments that fall within the true spirit and scope of the present invention. Thus, to the maximum extent allowed by law, the scope of the present invention is to be determined by the broadest permissible interpretation of the following claims and their equivalents, and shall not be restricted or limited by the foregoing detailed description.

Claims
  • 1. An osteoimplant comprising: a plurality of partially demineralized bone fibers in a remineralized matrix material, wherein each fiber has an elongated, thin body having a length of about 1 centimeter to about 3 centimeters, wherein the plurality of partially demineralized bone fibers are chemically crosslinked with a chemical cross-linker, wherein plurality of fibers engage to establish the matrix material, the matrix material having a porous structure throughout the internal structure of the matrix having pores of about 3.0 mm to about 5.0 mm diameter, and the osteoimplant has a compression resistance of about 10 MPa, and the length of the fibers are spatially arranged in a random-orientation, and the matrix comprises collagen dispersed within an internal structure of the matrix.
  • 2. The osteoimplant of claim 1, wherein the partially demineralized fibers are formed from an allogenic source.
  • 3. The osteoimplant of claim 1, wherein the partially demineralized fibers have about 20% to about 90% of an original mineral content removed.
  • 4. The osteoimplant of claim 1, wherein the chemical crosslinker includes glutaraldehyde, genipin, formaldehyde, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide/N -hydroxysuccinimide (EDC/NHS), or a combination thereof.
  • 5. The osteoimplant of claim 1, further comprising an osteoconductive mineral salt incorporated within the matrix material.
  • 6. The osteoimplant of claim 5, wherein the osteoconductive mineral salt is calcium salt.
  • 7. The osteoimplant of claim 1, having a degradation rate of about 20% six months after implantation.
  • 8. The osteoimplant of claim 1, wherein the collagen is a freeze-dried collagen.
  • 9. The osteoimplant of claim 8, wherein the freeze-dried collagen further comprises osteoconductive ceramic particles.
  • 10. The osteoimplant of claim 1, further comprising an additive.
  • 11. The osteoimplant of claim 10, wherein the additive comprises a radiocontrast medium, a drug, a cellular matter, a biological factor, or a combination thereof.
  • 12. The osteoimplant of claim 11, wherein the drug comprises an antibiotics, an analgesics, an anti-inflammatory drugs, an anti-TNF-alpha, a steroid, or a combination thereof.
  • 13. The osteoimplant of claim 11, wherein the biological factor comprises bone morphogenetic protein (BMP), growth differentiation factor (GDF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), LIM mineralization protein, fibroblast growth factor (FGF), osteoblast growth factor, or a combination thereof.
US Referenced Citations (106)
Number Name Date Kind
4624255 Schenck et al. Nov 1986 A
4742054 Naftchi May 1988 A
4863457 Lee Sep 1989 A
5263984 Li et al. Nov 1993 A
5522844 Johnson Jun 1996 A
5571882 Vetter Nov 1996 A
5626838 Cavanaugh, Jr. May 1997 A
5759583 Iwamoto et al. Jun 1998 A
5868789 Huebner Feb 1999 A
5942241 Chasin et al. Aug 1999 A
6069129 Sandberg et al. May 2000 A
6123731 Boyce et al. Sep 2000 A
6179862 Sawhney Jan 2001 B1
6180606 Chen et al. Jan 2001 B1
6248345 Goldenheim et al. Jun 2001 B1
6268405 Yao Jul 2001 B1
6287588 Shih et al. Sep 2001 B1
6326020 Kohane et al. Dec 2001 B1
6331311 Brodbeck et al. Dec 2001 B1
6428804 Suzuki et al. Aug 2002 B1
6440444 Boyce et al. Aug 2002 B2
6461631 Dunn et al. Oct 2002 B1
6524607 Goldenheim et al. Feb 2003 B1
6534081 Goldenheim et al. Mar 2003 B2
6589549 Shih et al. Jul 2003 B2
6616946 Meier et al. Sep 2003 B1
6630155 Chandrashekar et al. Oct 2003 B1
6632457 Sawhney Oct 2003 B1
6652883 Goupil et al. Nov 2003 B2
6676971 Goupil et al. Jan 2004 B2
6696073 Boyce et al. Feb 2004 B2
6710126 Hirt et al. Mar 2004 B1
6723741 Jeon et al. Apr 2004 B2
6723814 Meier et al. Apr 2004 B2
6756058 Brubaker et al. Jun 2004 B2
6773714 Dunn et al. Aug 2004 B2
6843807 Boyce et al. Jan 2005 B1
6863694 Boyce et al. Mar 2005 B1
6921541 Chasin et al. Jul 2005 B2
6974462 Sater Dec 2005 B2
7045141 Merboth et al. May 2006 B2
7070809 Goupil et al. Jul 2006 B2
7144412 Wolf et al. Dec 2006 B2
7166570 Hunter et al. Jan 2007 B2
7220281 Lambrecht et al. May 2007 B2
7229441 Trieu et al. Jun 2007 B2
7235043 Gellman et al. Jun 2007 B2
7287983 Ilan Oct 2007 B2
7318840 McKay Jan 2008 B2
7329259 Cragg Feb 2008 B2
7361168 Makower et al. Apr 2008 B2
7367978 Drewry et al. May 2008 B2
7658765 Lambrecht et al. Feb 2010 B2
8008357 Shoji et al. Aug 2011 B2
20020009454 Boone et al. Jan 2002 A1
20020090398 Dunn et al. Jul 2002 A1
20020122771 Holland et al. Sep 2002 A1
20030022927 Jeon et al. Jan 2003 A1
20030185873 Chasin et al. Oct 2003 A1
20030204191 Sater et al. Oct 2003 A1
20030224033 Li et al. Dec 2003 A1
20040072799 Li et al. Apr 2004 A1
20040082540 Hermida Ochoa Apr 2004 A1
20040109893 Chen et al. Jun 2004 A1
20040146543 Shimp Jul 2004 A1
20040214793 Hermida Ochoa Oct 2004 A1
20050059744 Donello et al. Mar 2005 A1
20050129656 Goupil et al. Jun 2005 A1
20050142163 Hunter et al. Jun 2005 A1
20050175709 Baty, III et al. Aug 2005 A1
20050186261 Avelar et al. Aug 2005 A1
20050197293 Mellis et al. Sep 2005 A1
20050222684 Ferree Oct 2005 A1
20050240269 Lambrecht et al. Oct 2005 A1
20050287218 Chaouk et al. Dec 2005 A1
20050288789 Chaouk et al. Dec 2005 A1
20060030948 Manrique et al. Feb 2006 A1
20060074422 Story et al. Apr 2006 A1
20060106361 Muni et al. May 2006 A1
20060148903 Burch et al. Jul 2006 A1
20060183786 Wang Aug 2006 A1
20060189944 Campbell et al. Aug 2006 A1
20060228391 Seyedin et al. Oct 2006 A1
20070004790 Chow et al. Jan 2007 A1
20070093907 Goupil et al. Apr 2007 A1
20070150061 Trieu Jun 2007 A1
20070156180 Jaax et al. Jul 2007 A1
20070185497 Cauthen et al. Aug 2007 A1
20070202074 Shalaby Aug 2007 A1
20070243225 McKay Oct 2007 A1
20070243228 McKay Oct 2007 A1
20070248639 Demopulos et al. Oct 2007 A1
20070253994 Hildebrand Nov 2007 A1
20070254041 Drapeau et al. Nov 2007 A1
20080021074 Cartt Jan 2008 A1
20080058953 Scarborough Mar 2008 A1
20080091207 Truckai et al. Apr 2008 A1
20080097229 Roy et al. Apr 2008 A1
20080147197 McKay Jun 2008 A1
20080188945 Boyce et al. Aug 2008 A1
20080269717 Crandall et al. Oct 2008 A1
20090020076 Ghiraldi Jan 2009 A1
20090155378 Behnam et al. Jun 2009 A1
20090222096 Trieu Sep 2009 A1
20090264489 Zanella Oct 2009 A1
20090275913 Trieu Nov 2009 A1
Foreign Referenced Citations (6)
Number Date Country
WO9639203 Dec 1996 WO
03005961 Jan 2003 WO
2005034998 Apr 2005 WO
WO2005097217 Oct 2005 WO
2007005177 Jan 2007 WO
2007076272 Jul 2007 WO
Non-Patent Literature Citations (8)
Entry
Williams Biomaterials, Aug. 2005;26(23):4817-27.
Murphy et al Cell Adh Migr. 2010 Jul.-Sep.; 4(3): 377-381.
Atrigel, QTL, Inc. Drug Delivery Platform, Jul. 2006 revision,QTL USA, Inc. Fort Collins, CO.
Medline, Pharmacological Approaches: http://www.medscape.com/viewarticle/552267—3.
Elizabeth A. Moberg-Wolff, M.D.; emedicine Article-Spasticity pp. 1-15.
Daniel P. Moore, M.D.; Helping your patients with spasticity reach maximal function, Aug. 1998, pp. 1-9, vol. 104, No. 2. http://www.postgraduate.com/issue/1998/08—98/moore,htm.
Kyphon, Enhanced Discyphor Catheter System, Kyphon Inc. 2007, Sunnyvale, CA.
Skedros, John G. et al. “The influence of collagen fiber orientation and other histocompositional characteristics on the mechanical properties of equine cortical bone,” Journal of Experimental Biology, Aug. 1, 2006, 209:3025-3042.
Related Publications (1)
Number Date Country
20110182963 A1 Jul 2011 US